TFG Asset Management GP Ltd Buys 250,000 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)

TFG Asset Management GP Ltd lifted its position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 3.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,250,000 shares of the company's stock after acquiring an additional 250,000 shares during the quarter. Autolus Therapeutics accounts for approximately 4.2% of TFG Asset Management GP Ltd's holdings, making the stock its 5th largest position. TFG Asset Management GP Ltd owned 3.10% of Autolus Therapeutics worth $19,388,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in AUTL. Wellington Management Group LLP raised its stake in Autolus Therapeutics by 4.6% during the fourth quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company's stock worth $59,562,000 after acquiring an additional 1,125,454 shares during the period. FMR LLC grew its holdings in shares of Autolus Therapeutics by 44.6% during the third quarter. FMR LLC now owns 17,773,873 shares of the company's stock valued at $64,519,000 after purchasing an additional 5,478,706 shares during the last quarter. Candriam S.C.A. acquired a new stake in shares of Autolus Therapeutics during the 4th quarter worth approximately $7,500,000. AXA S.A. bought a new stake in shares of Autolus Therapeutics in the 4th quarter worth approximately $4,288,000. Finally, Millennium Management LLC boosted its position in Autolus Therapeutics by 91.6% during the 4th quarter. Millennium Management LLC now owns 1,653,241 shares of the company's stock valued at $3,885,000 after purchasing an additional 790,437 shares during the period. 72.83% of the stock is currently owned by institutional investors.

Remove Ads

Autolus Therapeutics Price Performance

NASDAQ:AUTL remained flat at $1.94 during midday trading on Tuesday. The company had a trading volume of 1,050,323 shares, compared to its average volume of 1,380,899. The company has a market cap of $516.22 million, a P/E ratio of -1.60 and a beta of 2.07. Autolus Therapeutics plc has a 1 year low of $1.68 and a 1 year high of $6.63. The company's 50 day moving average price is $2.13 and its 200-day moving average price is $3.03.

Wall Street Analyst Weigh In

AUTL has been the topic of a number of recent research reports. Needham & Company LLC reiterated a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, January 13th. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Finally, Redburn Atlantic upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price for the company in a research report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $10.40.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.